Ovaleap ( follitropin alfa) was added to TEVA's portfolio in 2009 when they acquired Ratiopharm. How did TEVA make the deal on this drug before they even owned the rights?
Here is the list of biosimilars: pg. 15
"Biosimilars – Regulation strategies and pathway in the EU (and US) Experience gained and Perspectives"